Prednisone
Treatment for Lupus
Typical Dosage: 5-60 mg daily, tapering
Effectiveness
90%
Safety Score
45%
Clinical Trials
56
Participants
75K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
45
DangerousModerateSafe
Treatment Details
Dosage Range
5-60 mg daily, tapering
Time to Effect
Hours to days
Treatment Duration
Weeks for acute flares, lifetime for chronic low-dose
Evidence Quality
HIGHNumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
8(Treat 8 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$75
Monitoring:$600
Side Effect Mgmt:$750
Total Annual:$1,425
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODQALYs Gained
0.5
Outcome-Based Costs
Cost per Responder
$1,676
Prednisone Outcomes
for Lupus
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+85%
Common Side Effects
Weight gain, fluid retention
+60%
Mood changes, insomnia
+40%
Increased infection risk
+30%
Osteoporosis, diabetes, hypertension (long-term)
+20%
Sources:
Active Clinical Trials
2 active trials recruiting for Prednisone in Lupus
A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE Participants
NCT06625671RECRUITINGPHASE1, PHASE2
148 participants
INTERVENTIONAL
Clearwater, United States +3 more
Started: Oct 4, 2024
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis
NCT04221477ACTIVE NOT RECRUITINGPHASE3
271 participants
INTERVENTIONAL
Birmingham, United States +73 more
Started: Aug 10, 2020
Completed Clinical Trials
12 completed trials for Prednisone in Lupus
A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE
NCT03098823COMPLETEDPHASE4
62 participants
INTERVENTIONAL
Los Angeles, United States +20 more
Started: Sep 12, 2017
Serologically Active, Clinically Stable Systemic Lupus Erythematosus
NCT00000421COMPLETEDPHASE2
154 participants
INTERVENTIONAL
New Hyde Park, United States +2 more
Started: Sep 1, 1997
Induction Treatment of Proliferative Lupus Nephritis With Leflunomide Combined With Prednisone
NCT00268567COMPLETEDPHASE2, PHASE3
INTERVENTIONAL
Beijing, China +7 more
Started: Oct 1, 2002
Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Combination With Two Corticosteroid Regimens for the Treatment of Lupus Nephritis Flare
NCT00423098COMPLETEDPHASE2
81 participants
INTERVENTIONAL
Bogotá, Colombia +16 more
Started: Feb 1, 2007
Rituximab and Belimumab for Lupus Nephritis
NCT02260934COMPLETEDPHASE2
43 participants
INTERVENTIONAL
Birmingham, United States +14 more
Started: Jul 9, 2015
A Study to Compare the Efficacy and Safety of Tacrolimus Capsules and Cyclophosphamide Injection in Treatment of Lupus Nephritis
NCT02457221COMPLETEDPHASE3
314 participants
INTERVENTIONAL
Hefei, China +34 more
Started: Mar 10, 2015
Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis
NCT00774852COMPLETEDPHASE2
137 participants
INTERVENTIONAL
Birmingham, United States +22 more
Started: Nov 1, 2008
Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With Prednisone
NCT00119678COMPLETEDPHASE2
183 participants
INTERVENTIONAL
Tucson, United States +51 more
Started: Sep 1, 2005
A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis
NCT01085097COMPLETEDPHASE2
46 participants
INTERVENTIONAL
Phoenix, United States +29 more
Started: Sep 1, 2010
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus
NCT00137969COMPLETEDPHASE2, PHASE3
262 participants
INTERVENTIONAL
Birmingham, United States +64 more
Started: May 10, 2005
A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)
NCT02550652COMPLETEDPHASE2
126 participants
INTERVENTIONAL
La Jolla, United States +45 more
Started: Nov 13, 2015
A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV Lupus Nephritis
NCT00282347COMPLETEDPHASE3
144 participants
INTERVENTIONAL
Started: Jan 1, 2006
Showing 20 of 57 total trials